Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Ranolazine for Symptomatic Management of Microvascular Angina

Rayner-Hartley, Erin MD; Parvand, Mahraz BSc; Humphries, Karin H. DSc; Starovoytov, Andrew MD; Park, Julie E. MMath; Sedlak, Tara MD*

doi: 10.1097/MJT.0000000000000779
Original Investigation: PDF Only
Buy
PAP

Background: Ranolazine is approved in the United States and Europe for chronic stable angina. Microvascular angina (MVA) is defined as angina with no obstructive coronary artery disease.

Study Question: Our objective was to assess the effectiveness of ranolazine at improving angina scores and quality of life in a Canadian cohort with severe refractory angina due to MVA.

Study Design: We administered questionnaires to 31 patients at baseline and after at least 6 weeks of ranolazine treatment.

Measures and Outcomes: Validated, clinically significant changes for each Seattle Angina Questionnaire domain and the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form were obtained from the literature. Score changes between baseline and postranolazine use were analyzed using sign test.

Results: Patients were mostly female (27 of 31 patients) with a median age of 57 years. After initiation of ranolazine treatment, patients experienced improvements in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form scores (80.6%; P < 0.01) and in 3 of the 4 domains of the Seattle Angina Questionnaire (physical limitation: 73.3%; P = 0.02; treatment satisfaction: 80.6%; P < 0.01; and disease perception: 77.4%; P < 0.01). Patients were less likely to have interactions with the health care system after ranolazine treatment as compared with before (35.5% vs. 93.5%; P < 0.01).

Conclusions: Ranolazine significantly improves symptom control and quality of life in patients with MVA and severe refractory angina and reduces their interaction with the health care system. Given the potentially debilitating effect of chronic angina in MVA, ranolazine may be an effective treatment option.

Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, BC, Canada.

Address for correspondence: Division of Cardiology, Vancouver General Hospital, DHHC, 2775 Laurel Street, Level 9, Vancouver, BC, V5Z 1M9. E-mail: tara.sedlak@vch.ca

Supported by an Investigator-Sponsored research grant from Gilead Sciences, Inc. Statistical support was provided by the BC Centre for Improved Cardiovascular Health.

The authors have no conflicts of interest to declare.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.